Evidence map›Paper›PMID 40993021›Full record

ArticleCancer letters2025

Corrigendum to "Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 Inhibits prostate cancer stem cell-induced tumor growth" [Cancer Lett. 2017 Aug 11;406:71-80].

Gulzar Ahmad, Rana El Sadda, Galina Botchkina, Iwao Ojima, James Egan, Mansoor Amiji

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Gulzar AhmadDepartment of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA, 02115-5000, USA. Electronic address: gahmad2@yahoo.com.
Rana El SaddaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, USA. Electronic address: rana.elsadda@stonybrook.edu.
Galina BotchkinaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, USA; Department of Pathology, School of Medicine, Stony Brook University, Stony Brook, NY, 11794-8691, USA. Electronic address: Galina.Botchkina@stonybrookmedicine.edu.
Iwao OjimaInstitute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, 11794-3400, USA; Department of Chemistry, Stony Brook University, Stony Brook, NY, 11794-3400, USA. Electronic address: iwao.ojima@stonybrook.edu.
James EganTargagenix, Inc., 25 Health Sciences Drive, Stony Brook, NY, 11790-3382, USA. Electronic address: jegan@targagenix.com.
Mansoor AmijiDepartment of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA, 02115-5000, USA. Electronic address: m.amiji@northeastern.edu.

Funding

Tumor -Targeting Chemotherapeutic AgentsR01CA103314 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI OJIMA, IWAO · 2003 to 2013
$3.1M
NCI NIH HHS R01 CA103314
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40993021
PMCPMC12993433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.